Header Logo

Connection

BULENT OZPOLAT to Animals

Back to Details
This is a "connection" page, showing publications BULENT OZPOLAT has written about Animals.
BULENT OZPOLAT
Connection Strength
0.610
Animals
  1. miRNA-193b-5p Suppresses Pancreatic Cancer Cell Proliferation, Invasion, Epithelial Mesenchymal Transition, and Tumor Growth by Inhibiting eEF2K. Anticancer Agents Med Chem. 2022; 22(14):2607-2618.
    View in: PubMed
    Score: 0.036
  2. Targeting eukaryotic elongation factor-2 kinase suppresses the growth and peritoneal metastasis of ovarian cancer. Cell Signal. 2021 05; 81:109938.
    View in: PubMed
    Score: 0.034
  3. Eukaryotic elongation factor-2 kinase (eEF2K) signaling in tumor and microenvironment as a novel molecular target. J Mol Med (Berl). 2020 06; 98(6):775-787.
    View in: PubMed
    Score: 0.032
  4. MicroRNA-based Targeted Therapeutics in Pancreatic Cancer. Anticancer Res. 2019 Feb; 39(2):529-532.
    View in: PubMed
    Score: 0.030
  5. Elongation factor-2 kinase (eEF-2K) expression is associated with poor patient survival and promotes proliferation, invasion and tumor growth of lung cancer. Lung Cancer. 2018 10; 124:31-39.
    View in: PubMed
    Score: 0.028
  6. Thymoquinone inhibits cell proliferation, migration, and invasion by regulating the elongation factor 2 kinase (eEF-2K) signaling axis in triple-negative breast cancer. Breast Cancer Res Treat. 2018 Oct; 171(3):593-605.
    View in: PubMed
    Score: 0.028
  7. Dual Suppressive Effect of miR-34a on the FOXM1/eEF2-Kinase Axis Regulates Triple-Negative Breast Cancer Growth and Invasion. Clin Cancer Res. 2018 09 01; 24(17):4225-4241.
    View in: PubMed
    Score: 0.028
  8. Pancreatic Cancer Stem Cells and Therapeutic Approaches. Anticancer Res. 2017 06; 37(6):2761-2775.
    View in: PubMed
    Score: 0.026
  9. MicroRNA 603 acts as a tumor suppressor and inhibits triple-negative breast cancer tumorigenesis by targeting elongation factor 2 kinase. Oncotarget. 2017 Feb 14; 8(7):11641-11658.
    View in: PubMed
    Score: 0.026
  10. FOXM1 regulates expression of eukaryotic elongation factor 2 kinase and promotes proliferation, invasion and tumorgenesis of human triple negative breast cancer cells. Oncotarget. 2016 Mar 29; 7(13):16619-35.
    View in: PubMed
    Score: 0.024
  11. Liposomal siRNA nanocarriers for cancer therapy. Adv Drug Deliv Rev. 2014 Feb; 66:110-6.
    View in: PubMed
    Score: 0.021
  12. Targeted silencing of elongation factor 2 kinase suppresses growth and sensitizes tumors to doxorubicin in an orthotopic model of breast cancer. PLoS One. 2012; 7(7):e41171.
    View in: PubMed
    Score: 0.019
  13. Targeting the prodeath and prosurvival functions of autophagy as novel therapeutic strategies in cancer. Autophagy. 2010 Apr; 6(3):322-9.
    View in: PubMed
    Score: 0.016
  14. Nanomedicine based approaches for the delivery of siRNA in cancer. J Intern Med. 2010 Jan; 267(1):44-53.
    View in: PubMed
    Score: 0.016
  15. Liposomal cytokines and liposomes targeted to costimulatory molecules as adjuvants for human immunodeficiency virus subunit vaccines. Methods Enzymol. 2003; 373:92-100.
    View in: PubMed
    Score: 0.010
  16. Simvastatin-loaded liposome nanoparticles treatment for uterine leiomyoma in a patient-derived xenograft mouse model: a pilot study. J Obstet Gynaecol. 2022 Aug; 42(6):2139-2143.
    View in: PubMed
    Score: 0.009
  17. Redirecting host preexisting influenza A virus immunity for cancer immunotherapy. Cancer Immunol Immunother. 2022 Jul; 71(7):1611-1623.
    View in: PubMed
    Score: 0.009
  18. Stress-Mediated Reprogramming of Prostate Cancer One-Carbon Cycle Drives Disease Progression. Cancer Res. 2021 08 01; 81(15):4066-4078.
    View in: PubMed
    Score: 0.009
  19. Current strategies to circumvent the antiviral immunity to optimize cancer virotherapy. J Immunother Cancer. 2021 04; 9(4).
    View in: PubMed
    Score: 0.009
  20. Non-coding RNAs regulation of macrophage polarization in cancer. Mol Cancer. 2021 02 01; 20(1):24.
    View in: PubMed
    Score: 0.008
  21. Quantitative and bioluminescent assay to measure efficacy of conventional and DNA vaccinations against Helicobacter pylori. Comb Chem High Throughput Screen. 2000 Aug; 3(4):289-302.
    View in: PubMed
    Score: 0.008
  22. Liposomal 2-Methoxyestradiol Nanoparticles for Treatment of Uterine Leiomyoma in a Patient-Derived Xenograft Mouse Model. Reprod Sci. 2021 01; 28(1):271-277.
    View in: PubMed
    Score: 0.008
  23. Quantitation of Helicobacter pylori in the stomach using quantitative polymerase chain reaction assays. Helicobacter. 2000 Mar; 5(1):13-21.
    View in: PubMed
    Score: 0.008
  24. Targeting the TMPRSS2/ERG fusion mRNA using liposomal nanovectors enhances docetaxel treatment in prostate cancer. Prostate. 2020 01; 80(1):65-73.
    View in: PubMed
    Score: 0.008
  25. Therapeutic targeting of the PI4K2A/PKR lysosome network is critical for misfolded protein clearance and survival in cancer cells. Oncogene. 2020 01; 39(4):801-813.
    View in: PubMed
    Score: 0.008
  26. EF2-kinase targeted cobalt-ferrite siRNA-nanotherapy suppresses BRCA1-mutated breast cancer. Nanomedicine (Lond). 2019 09; 14(17):2315-2338.
    View in: PubMed
    Score: 0.008
  27. Regulation of the unfolded protein response through ATF4 and FAM129A in prostate cancer. Oncogene. 2019 08; 38(35):6301-6318.
    View in: PubMed
    Score: 0.008
  28. Oncogenic and osteolytic functions of histone demethylase NO66 in castration-resistant prostate cancer. Oncogene. 2019 06; 38(25):5038-5049.
    View in: PubMed
    Score: 0.007
  29. Genistein Prevents Development of Spontaneous Ovarian Cancer and Inhibits Tumor Growth in Hen Model. Cancer Prev Res (Phila). 2019 03; 12(3):135-146.
    View in: PubMed
    Score: 0.007
  30. Exosomal miRNA confers chemo resistance via targeting Cav1/p-gp/M2-type macrophage axis in ovarian cancer. EBioMedicine. 2018 Dec; 38:100-112.
    View in: PubMed
    Score: 0.007
  31. Immunoliposomes containing antibodies to costimulatory molecules as adjuvants for HIV subunit vaccines. AIDS Res Hum Retroviruses. 1998 Mar 20; 14(5):409-17.
    View in: PubMed
    Score: 0.007
  32. A promising natural product, pristimerin, results in cytotoxicity against breast cancer stem cells in vitro and xenografts in vivo through apoptosis and an incomplete autopaghy in breast cancer. Pharmacol Res. 2018 03; 129:500-514.
    View in: PubMed
    Score: 0.007
  33. Chemopreventive and Antitumor Efficacy of Curcumin in a Spontaneously Developing Hen Ovarian Cancer Model. Cancer Prev Res (Phila). 2018 01; 11(1):59-67.
    View in: PubMed
    Score: 0.007
  34. Modified gold-based siRNA nanotherapeutics for targeted therapy of triple-negative breast cancer. Nanomedicine (Lond). 2017 Aug; 12(16):1961-1973.
    View in: PubMed
    Score: 0.007
  35. Exosomal miR-940 maintains SRC-mediated oncogenic activity in cancer cells: a possible role for exosomal disposal of tumor suppressor miRNAs. Oncotarget. 2017 Mar 21; 8(12):20145-20164.
    View in: PubMed
    Score: 0.006
  36. Ubiquitous Release of Exosomal Tumor Suppressor miR-6126 from Ovarian Cancer Cells. Cancer Res. 2016 12 15; 76(24):7194-7207.
    View in: PubMed
    Score: 0.006
  37. Oligonucleotide-based theranostic nanoparticles in cancer therapy. Nanomedicine (Lond). 2016 05; 11(10):1287-308.
    View in: PubMed
    Score: 0.006
  38. Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition). Autophagy. 2016; 12(1):1-222.
    View in: PubMed
    Score: 0.006
  39. Erythropoietin Stimulates Tumor Growth via EphB4. Cancer Cell. 2015 Nov 09; 28(5):610-622.
    View in: PubMed
    Score: 0.006
  40. STAMP2 increases oxidative stress and is critical for prostate cancer. EMBO Mol Med. 2015 Mar; 7(3):315-31.
    View in: PubMed
    Score: 0.006
  41. Preclinical and clinical development of siRNA-based therapeutics. Adv Drug Deliv Rev. 2015 Jun 29; 87:108-19.
    View in: PubMed
    Score: 0.006
  42. Rac1/Pak1/p38/MMP-2 Axis Regulates Angiogenesis in Ovarian Cancer. Clin Cancer Res. 2015 May 01; 21(9):2127-37.
    View in: PubMed
    Score: 0.006
  43. Bisphosphonates inhibit stellate cell activity and enhance antitumor effects of nanoparticle albumin-bound paclitaxel in pancreatic ductal adenocarcinoma. Mol Cancer Ther. 2014 Nov; 13(11):2583-94.
    View in: PubMed
    Score: 0.005
  44. Nanotechnology in cancer therapy. J Drug Target. 2013 Dec; 21(10):904-13.
    View in: PubMed
    Score: 0.005
  45. Highly specific targeting of the TMPRSS2/ERG fusion gene using liposomal nanovectors. Clin Cancer Res. 2012 Dec 15; 18(24):6648-57.
    View in: PubMed
    Score: 0.005
  46. Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy. 2012 Apr; 8(4):445-544.
    View in: PubMed
    Score: 0.005
  47. Paraneoplastic thrombocytosis in ovarian cancer. N Engl J Med. 2012 Feb 16; 366(7):610-8.
    View in: PubMed
    Score: 0.005
  48. Silencing of p130cas in ovarian carcinoma: a novel mechanism for tumor cell death. J Natl Cancer Inst. 2011 Nov 02; 103(21):1596-612.
    View in: PubMed
    Score: 0.004
  49. Targeting p70S6K prevented lung metastasis in a breast cancer xenograft model. Mol Cancer Ther. 2010 May; 9(5):1180-7.
    View in: PubMed
    Score: 0.004
  50. Guidelines for the use and interpretation of assays for monitoring autophagy in higher eukaryotes. Autophagy. 2008 Feb; 4(2):151-75.
    View in: PubMed
    Score: 0.003
  51. DNA vaccination against neu reduces breast cancer incidence and metastasis in mice. Cancer Gene Ther. 2001 Apr; 8(4):259-68.
    View in: PubMed
    Score: 0.002
  52. Development of a murine model of Helicobacter pylori infection. Helicobacter. 1997 Jun; 2(2):78-81.
    View in: PubMed
    Score: 0.002
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.